Blue light: Friend or foe ?

BACKGROUND: The purpose of this study was to elucidate why some potentially damaging and beneficial effects were obtained following blue light exposures on skin. MATERIALS AND METHODS: Light-emitting diode (LED) devices containing 415 and 470 nm bulbs were used on normal human keratinocytes, skin biopsies and subjects with acne. Reactive oxygen species (ROS) evaluation was performed after a course of blue LED light exposures. A comparison between very small bandwidth centered at 415 nm and a combination of (415 + 470 nm) wavelengths was also carried out regarding the effects on ROS production. The effects on other targets such as opsin1 short wavelength (OPN1 SW) photoreceptor, fibrillin-1 dermal component, LL37 antimicrobial peptide and interleukin-8 (IL-8) proinflammatory cytokine were then explored. Finally, clinical pictures of acne signs were also investigated after blue LED exposures. RESULTS: Dose dependent increases of ROS production were obtained on keratinocytes exposed to increasing 415 nm LED exposures. However, a ROS decreasing first phase was observed on keratinocytes exposed to 415 + 470 nm LED exposures. Moreover, comparing the same doses of 415 nm wavelength and (415 + 470 nm) wavelength combination, 415 nm alone is more damaging than the 415 + 470 nm exposures. In case of increase in ROS, decrease in OPN1 SW photoreceptor and fragmentation of fibrillin-1 dermal fiber were observed. When conditions of ROS decrease were experienced, an increase in LL37 antimicrobial peptide and a modulation of IL-8 inflammatory response were noted, suggesting improvement in acne signs. Clinical results confirmed the benefits on inflammatory lesions on subjects with acne. CONCLUSION: Blue lights can induce beneficial and adverse effects, depending on the dose and on the spectrum width of the exposure.

Treating multiple body parts for skin laxity and fat deposits using a novel focused radiofrequency device with an ultrasound component: Safety and efficacy study.

BACKGROUND AND OBJECTIVES: Growing demand for noninvasive skin tightening and reduction in fat results in an increasing pressure for devices with good clinical efficacy, consistency of results, and high patient comfort. The objective was to validate clinical efficacy and versatility of a novel device, which combines radiofrequency (RF) and ultrasound for treating skin laxity and fat deposits. METHODS: We treated 34 subjects with facial skin laxity and/or abundant body or arm fat deposits. Subjects were divided based on their indications. Ten subjects received treatments to the face, 7 subjects to arms, 8 subjects to thighs, and 9 subjects on abdomen. All patients received 4 treatments on a weekly basis. Photographs of patients were assessed by blinded evaluators to recognize the baseline images from the 3-month follow-up images. Patient comfort and satisfaction were evaluated using a 5-point Likert scale questionnaire. Any adverse events were recorded. RESULTS: Patient images were correctly recognized in >90% of cases in all study groups. Patient questionnaires showed overall satisfaction with the therapy course and results. On a scale of 1 to 5, the patients agreed (4.1) that they are satisfied with the results that the treatment is comfortable (4.1) and that they are satisfied with the treatment time (4.1). No adverse events were reported. CONCLUSIONS: Consistent clinical efficacy was confirmed across all the treated areas, together with high patient comfort and satisfaction. We conclude the device is a highly versatile solution that can deliver results across body parts and different indications.